NuVasive Management to Participate in Investor Events in

NuVasive Management to Participate in Investor Events in November and
December 2012 
SAN DIEGO, CA -- (Marketwire) -- 11/19/12 --  NuVasive, Inc. (NASDAQ:
NUVA), a medical device company focused on developing minimally
disruptive surgical products and procedures for the spine, announced
today that management will participate in the following investor
events in November and December 2012:  


 
--  The Piper Jaffray Healthcare Conference at the New York Palace Hotel
    in New York City on Tuesday, November 27, 2012, at 10:00 a.m. EST.
    
    
--  The RBC Capital Markets Healthcare Investor Day at the JW Marriot in
    Denver, Colorado, on Thursday, November 29, 2012.
    
    
--  Jefferies' San Diego MedTech Bus Tour at NuVasive's headquarters in
    San Diego, CA, on Monday, December 3, 2012, at 11:00 a.m. PT.
    
    
--  Leerink Swan's Devices and DNA Bus Tour at NuVasive's headquarters in
    San Diego, CA, on Tuesday, December 11, 2012, at 10:00 a.m. PT.

  
Alive webcast of the Piper Jaffray presentation and of each of the Bus
Tours will be available online from the investor relations page of
the Company's corporate website at www.nuvasive.com. After the live
webcasts, a replay of the presentations will remain available on the
website for 30 days.  
About NuVasive 
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $7.9
billion global spine market. 
NuVasive's principal product offering is based on its Maximum Access
Surgery, or MAS(R) platform. The MAS platform combines several
categories of solutions that collectively minimize soft tissue
disruption during spine surgery with maximum visualization and safe,
easy reproducibility for the surgeon: a proprietary software-driven
nerve avoidance system and intra-operative monitoring support;
MaXcess(R), a unique split-blade retractor system; a wide variety of
specialized implants; and several biologic fusion enhancers. MAS
significantly reduces surgery time and returns patients to activities
of daily living much faster than conventional approaches. Having
redefined spine surgery with the MAS platform's lateral approach,
known as eXtreme Lateral Interb
ody Fusion, or XLIF(R), NuVasive has
built an entire spine franchise. With over 75 products today spanning
lumbar, thoracic and cervical applications, the Company will continue
to expand and evolve its offering predicated on its R&D focus and
dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R). 
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
uncertain process of seeking regulatory approval or clearance for
NuVasive's products or devices, including risks that such process
could be significantly delayed; the possibility that the FDA may
require significant changes to NuVasive's products or clinical
studies; the risk that products may not perform as intended and may
therefore not achieve commercial success; the risk that competitors
may develop superior products or may have a greater market position
enabling more successful commercialization; the risk that insurance
payers may refuse to reimburse healthcare providers for the use of
NuVasive's products the risk that additional clinical data may call
into question the benefits of NuVasive's products to patients,
hospitals and surgeons; and other risks and uncertainties more fully
described in NuVasive's press releases and periodic filings with the
Securities and Exchange Commission. NuVasive's public filings with
the Securities and Exchange Commission are available at www.sec.gov.
NuVasive assumes no obligation to update any forward-looking
statement to reflect events or circumstances arising after the date
on which it was made. 
Contact:
Michael J. Lambert
EVP & Chief Financial Officer
NuVasive, Inc.
858.909.3394
investorrelations@nuvasive.com  
Investors:
Stephan Ogilvie 
VP, Corporate Development & Investor Relations
NuVasive, Inc.
201-322-6515
investorrelations@nuvasive.com  
Media:
Nicholas S. Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.